bluuebunny/crossref_metadata_2025_split huggingface dataset:
Assessing the Portion of Diet Taken by Birds and Mammals from a Pesticide-Treated Area—Proposal for a Joint Way Forward
Authors: Ludwigs Jan-Dieter , Ebeling Markus , Haaf Sonja , Kragten Steven 
Published: February 2022

Abstract
An environmental risk assessment for birds and mammals is an important part of any application package for potential registration of pesticides in Europe. A realistic estimation of the exposure of a certain species to the pesticide under field conditions is a refinement factor in long-term higher-tier risk assessments. Although guidance on how to collect specific exposure data is provided, there is not yet a harmonized view on how to use and assess existing and newly recorded field data. Exposure is defined as the portion of diet taken from a pesticide-treated crop field over time (the PT factor), and it is set equal to the time a (tracked) individual is active (= foraging) in the crop of concern at the crop growth stage relevant to the pesticide application being assessed. While the PT factor is set to 1 in a first tier, it can be refined in higher tiers. Differences in the methodologies influencing the robustness of a data set and intraindividual variance in PT data are currently not considered. Our study, based on data recording in accordance with the European Food Safety Authority's recommendations, shows this variance for different species in different crops for both breeding and nonbreeding periods, with tracking sessions showing both interindividual as well as intraindividual variation across several days. We discuss PT data quality and how it can be used, considering intraindividual variance in a manner that is protective and conforms to current European guidance. The present study intends to support the planned revision of the current European guidance on how to conduct environmental bird and mammal risk assessments, and its further purpose is to open constructive discussions about how and which kind of PT data can be used. Environ Toxicol Chem 2022;41:1344–1354. © 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
Meta-analysis of Bioaccumulation Data for Nondissolvable Engineered Nanomaterials in Freshwater Aquatic Organisms
Authors: Zheng Yuanfang , Nowack Bernd 
Published: February 2022

Abstract
Understanding the bioaccumulation of engineered nanomaterials (ENMs) is essential for making regulatory decisions on potential environmental risks. Research in the field of ENM bioaccumulation has increased in recent years, but the compilation and statistical analysis of the available experimental data have not been updated. We therefore performed a meta-analysis of the existing literature on the bioaccumulation of eight types of nondissolvable ENMs (titanium dioxide [TiO2], aluminum oxide [Al2O3], gold [Au], fullerene [C60], carbon nanotubes, iron oxide [FeOx], graphene, and polystyrene) in nonmammalian freshwater aquatic organisms across three trophic levels including phytoplankton, zooplankton, and fish. Three typical endpoints were used to assess the bioaccumulation potential: the bioconcentration factor (BCF), the bioaccumulation factor (BAF), and the biomagnification factor (BMF). Our results suggest that zooplankton has greater mean logarithmic BCF and BAF values than phytoplankton (3.31 vs. 1.42) and fish (2.04). The ENMs are biomagnified in zooplankton, with a mean BMF of 17.4, whereas trophic transfer from primary consumers (zooplankton) to secondary consumers (fish) was not observed (mean BMF of 0.13). No clear dependency was identified between the physicochemical characteristics of ENMs (e.g., primary particle size, zeta potential, or shape) and bioaccumulation, except for coated versus uncoated particles accumulated in phytoplankton. Carbonaceous ENMs were found to be more bioaccumulated than the other ENMs we considered, except for TiO2. A meta-analysis of bioaccumulation data can (1) deepen the understanding of bioconcentration, bioaccumulation, and biomagnification of ENMs, (2) be used to support grouping strategies as a basis for a safer-by-design approach for ENMs, (3) be integrated into comprehensive hazard and risk assessments, (4) promote the standardization of testing guidelines, and (5) enhance future kinetic bioaccumulation modeling. Environ Toxicol Chem 2022;41:1202–1214. © 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
Abstract
Meta-analysis of bioaccumulation of non-dissolvable ENMs in non-mammalian freshwater aquatic organisms across three trophic levels including phytoplankton, zooplankton and fish. Three typical endpoints were used to assess the bioaccumulation potential: the bioconcentration factor (BCF), the bioaccumulation factor (BAF) and the biomagnification factor (BMF).
Invertebrate Species for the Bioavailability and Accumulation Assessment of Manufactured Polymer-Based Nano- and Microplastics
Authors: Kuehr Sebastian , Esser Dana , Schlechtriem Christian 
Published: February 2022

Abstract
Bioaccumulation tests with invertebrates have recently been discussed as a suitable alternative to bioaccumulation tests with metal- or metal oxide-based nanoparticles in fish for regulatory assessment. In the present study, as a first step, we investigated the suitability of three invertebrate species for bioaccumulation tests with nano- and microplastics. In a laboratory approach the freshwater bivalve Corbicula fluminea, the freshwater amphipod Hyalella azteca, and the terrestrial isopod Porcellio scaber were exposed to fluorescently labeled nano- and microplastics to evaluate their suitability to estimate the bioavailability and bioaccumulation of these test items. No bioaccumulation was observed in H. azteca or P. scaber. In contrast, the measurement of the relative fluorescence of the test items in the soft tissue and the feces of the filter-feeding bivalve allowed us to derive data that may be useful for the regulatory bioaccumulation assessment of manufactured nano- and microplastics. The developed measurement method using fluorescence represents a time-efficient and cost-effective analytical method for manufactured nano- and microplastics in laboratory studies for regulatory assessment. Environ Toxicol Chem 2022;41:961–974. © 2022 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.
Point, interval, and density forecasts: Differences in bias, judgment noise, and overall accuracy
Authors: Niu Xiaoxiao , Harvey Nigel 
Published: February 2022

AbstractThere are three main ways in which judgmental predictions are expressed: point forecasts; interval forecasts; probability density forecasts. Do these approaches differ solely in terms of their simplicity of elicitation and the detail they provide? We examined error in values of the central tendency extracted from these three types of forecast in a domain in which all of them are used: lay forecasts of inflation. A first experiment using a between‐participant design showed that the mean level of forecasts and the bias in them are unaffected by the type of forecast but that judgment noise (and, hence, overall error) is higher in point forecasts than in interval or density forecasts. A second experiment replicated the difference between point and interval forecasts in a within‐participant design (of the sort used in inflation surveys) and showed no effect of the order in which different types of forecast are made but revealed that people are more overconfident in interval than in point forecasts. A third experiment showed that volatility in past data increases bias in point but not interval forecasts, and that taking the average of two point forecasts made by an individual reduces judgment noise to the level found in interval forecasting.
A novel method of hard palate reconstruction utilizing a combination of the buccal fat pad and palatal island flap
Authors: Seo Gabriella T. , Beute John E. , Shaari Ariana L. , Mundi Neil , Urken Mark L. 
Published: February 2022

AbstractThe palatal island flap is reliable for single‐staged reconstruction of select oral defects. However, fistula formation is a disruptive potential complication. The authors employed this technique in five patients and present a representative case of a 65‐year‐old female with a left‐sided palatal salivary neoplasm. The patient underwent resection and was reconstructed utilizing a combination of the buccal fat pad and palatal island flap. Four of the five patients healed uneventfully. One patient experienced partial loss of the marginal zone of the palatal island flap which successfully granulated and did not lead to an oroantral fistula. The representative patient recovered uneventfully. At 2 weeks, she felt well, with no evidence of fistula. The anterior palate demonstrated early mucosalization. We present the novel, combined use of the palatal island flap and buccal fat pad flap to create a two‐layer closure and describe its advantages for posterior palate reconstruction.
Impact of secondary tumor‐free resection margins in soft tissue on local, regional, and distant recurrence in R0‐resected oral squamous cell carcinoma
Authors: Ooms Mark , Ponke Lisa , Puladi Behrus , Winnand Philipp , Heitzer Marius , Katz Marie Sophie , Hölzle Frank , Modabber Ali 
Published: February 2022

AbstractBackgroundThe impact of additional soft tissue resection on recurrence of oral squamous cell carcinoma (OSCC) remains controversial. The study aim was to compare recurrence between patients with secondary tumor‐free resection margins after intraoperative additional resection (STF‐RM) and patients with primary tumor‐free resection margins without additional resection (PTF‐RM).MethodsForty‐five patients with STF‐RM were matched with patients with PTF‐RM according to Union for International Cancer Control stage, tumor location, and treatment modality and compared for local, regional, and distant recurrence.ResultsPatients with STF‐RM showed lower local and distant control rates compared to patients with PTF‐RM (66.2% vs. 82.8%; p = 0.045 and 86.3% vs. 100.0%; p = 0.021). STF‐RM was the only predictor of local recurrence accounting for tumor (T) status, nodal (N) status, tumor grade, margin distance, and extracapsular extension (hazard ratio 4.21 [95% confidence interval 1.26–14.04]; p = 0.019).ConclusionsSTF‐RM have an adverse impact on local and distant recurrence of OSCC.
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study
Authors: Liu Jun , Li Jingpei , Lin Wanli , Shao Di , Depypere Lieven , Zhang Zhifeng , Li Zhuoyi , Cui Fei , Du Zesen , Zeng Yuan , Jiang Shunjun , He Ping , Gu Xia , Chen Huai , Zhang Hai , Lin Xiaowei , Huang Haoda , Lv Wenqiang , Cai Weiming , Liang Wenhua , Liang Hengrui , Jiang Wenxi , Wang Wei , Xu Ke , Cai Weipeng , Wu Kui , Lerut Toni , Fu Junhui , He Jianxing 
Published: February 2022

AbstractOptimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD‐1 blockade with neoadjuvant therapy. This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. Patients (clinical stage II‐IVA) received two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab‐paclitaxel (260 mg/m2 in total on day 1 and day 8) and cisplatin (75 mg/m2 in total on days 1‐3) of each 21‐day cycle. Surgery was performed approximately 6 weeks after completion of NIC. Primary endpoint was complete pathologic response (CPR) rate in primary tumor. Secondary endpoints were objective response rate (ORR) per RECIST v1.1, 2‐year progression‐free survival (PFS) rate after surgery, PFS, overall survival (OS) and safety during NIC and perioperative period. Between 17 January 2020 and 8 December 2020, 56 patients were enrolled, and 51 received esophagectomy. Data cutoff date was 25 August 2021. The CPR rate was 35.3% (95% CI, 21.7%‐48.9%). NIC had an ORR of 66.7% (95% CI, 40.0%‐70.4%) and treatment‐related adverse events (TRAEs) of low severity (grade 1‐2, 75.0%; grade 3, 10.7%; grade 4‐5, no). No perioperative mortality occurred. Three (5.9%) patients had tumor recurrence and one (2.0%) patient died. The 2‐year PFS rate, median PFS and median OS had not been reached yet. Camrelizumab plus neoadjuvant chemotherapy in resectable ESCC demonstrates promising efficacy with acceptable toxicity, providing a feasible and effective option. Study is ongoing for long‐term survival analyses.
Sodium benzoate induces neurobehavioral deficits and brain oxido‐inflammatory stress in male Wistar rats: Ameliorative role of ascorbic acid
Authors: Asejeje Folake O. , Ajayi Babajide O. , Abiola Michael A. , Samuel Omolola , Asejeje Gbolahan I. , Ajiboye Ebenezer O. , Ajayi Abayomi M. 
Published: February 2022

AbstractBackgroundSodium benzoate (SB) is a widely used food preservative. However, excessive intake of a high dose of SB poses a risk of neurotoxicity. Ascorbic acid (AA) is a naturally occurring antioxidant found in fruits with reported neuroprotective properties. The present study investigated the neurobehavioral and biochemical alterations in SB‐treated rats and the ameliorative effect of AA in rats.MethodsForty‐two male Wistar rats were divided into six groups (n = 7). Group 1 (vehicle, 10 ml/kg), Groups 2–4 rats SB (150, 300, and 600 mg/kg), Group 5 AA (100 mg/kg) and Group 6 (SB 600 mg/kg + AA 100 mg/kg). Treatment was daily administered for 28 days by oral route. Anxiogenic behavior, locomotor, and exploratory activities were evaluated in the open field monitored with a camera, and memory performance in Y‐maze. Brain oxidative stress, inflammatory, apoptosis, and cholinergic markers were determined. The cortico‐hippocampal tissues were examined histologically.ResultsSB‐treated rats showed significant anxiogenic‐like behavior and impairment in locomotor, exploratory, and memory performance. This was reversed in SB (600 mg/kg)‐treated rats coadministered with AA. SB‐treated rats showed a decrease in antioxidant enzyme activities, increase malondialdehyde (MDA), nitrite, tumor necrosis factor‐alpha, caspase‐3, and acetylcholinesterase activity in the striatum, hippocampus, frontal cortex, and cerebellum. These biochemical changes were reversed in AA‐treated rats. Reduced cortico‐hippocampal neuronal cell count and the pyknotic index were found in SB‐treated rats, which was also reversed in AA‐treated rats.ConclusionConclusively, sodium‐benzoate‐induced neurobehavioral deficits and brain biochemical changes were ameliorated by ascorbic acid probably via antioxidant, anti‐inflammatory, and apoptotic mechanisms.
Comparative performance of ELISA and dot blot assay for TSH‐receptor antibody detection in Graves’ disease
Authors: Zulkarnain Zulkarnain , Ulhaq Zulvikar Syambani , Sujuti Hidayat , Soeatmadji Djoko Wahono , Zufry Hendra , Wuragil Dyah Kinasih , Marhendra Agung Pramana W. , Riawan Wibi , Kurniawati Siti , Oktanella Yudit , Aulanni’am Aulanni’am 
Published: February 2022

AbstractBackgroundGraves’ disease (GD) is an autoimmune disease, and it accounts for major cases of hyperthyroidism. Antibody against thyroid‐stimulating hormone receptor/TSHR (TRAb) is responsible for hyperthyroidism and is considered as a diagnostic marker for GD. Therefore, we developed a recombinant protein of human TSHR‐169 (hTSHR‐169), which was specifically recognized TRAb in the serum of GD patients and then compare the diagnostic performance between ELISA and dot blot of TRAb tests for their ability to diagnose GD.Methods20 GD patients and 20 healthy individuals from the Indonesian population were enrolled. TRAb concentration and density were quantified. Comparative analysis was performed using receiver‐operating curve (ROC) analysis.ResultsFor dot blot assay, the minimum concentration to detect TRAb requiring 100 ng of antigen with antiserum diluted at 1:60. For diagnosing GD, the ELISA yielded a higher AUC compared with the dot blot assay (0.95 and 0.85, respectively). Using the recommended cutoff values, the efficiency of both assays was examined by comparing the specificity and sensitivity of the assays to the clinical diagnosis. The ELISA showed 80% and 95%, while the dot blot assay showed 70% and 95% sensitivity and specificity, respectively.ConclusionAlthough the dot blot assay exhibited lower performance than the ELISA method, the dot blot assay is a simple and rapid diagnostic assay that is suitable for diagnosing GD in rural areas, in which healthcare facilities sometimes are not accessible.
Prognostic nutrition index is associated with the all‐cause mortality in sepsis patients: A retrospective cohort study
Authors: Wu He , Zhou Chongjun , Kong Wanquan , Zhang Yi , Pan Da 
Published: February 2022

AbstractBackgroundThe study aimed at evaluating the prognostic utility of the prognostic nutritional index (PNI) for patients with sepsis.MethodsData in the present study were obtained from the Multiparameter Intelligent Monitoring in Intensive Care Database III. The calculation for PNI was as follows: serum albumin concentration (g/L) +0.005 × total lymphocyte count. 30‐day mortality was considered as the primary outcome, while 90‐day mortality and one‐year mortality were the secondary outcomes. Cox proportional risk models and propensity score matching (PSM) analyses were used to analyze the association between PNI and clinical outcomes in patients with sepsis. To assess the predictive value of PNI for 30‐day mortality, receiver operator characteristic (ROC) curve analysis was performed.ResultsA total of 2669 patients were in the study. After the confounding factors were adjusted, PNI ≥ 29.3 was identified as an independent predictive prognostic factor for the 30‐day all‐cause mortality (hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.56–0.76; p < 0.00001). Moreover, PSM analysis further validated the prognostic predictive value of PNI for patients with sepsis. The AUC of the PNI was 0.6436 (95% CI: 0.6204–0.6625) which was significantly high than the AUC of NLR (0.5962, 95% CI: 0.5717–0.6206) (p = 0.0031), the RDW (0.5878, 95% CI: 0.5629–0.6127) (p < 0.0001), and PLR (0.4979, 95% CI: 0.4722–0.5235) (p < 0.0001).ConclusionThe findings suggested that PNI was also a significant risk factor for sepsis.
COVID‐19 in HIV‐positive patients: A systematic review of case reports and case series
Authors: Heidary Mohsen , Asadi Arezoo , Noorbakhsh Negar , Dashtbin Shirin , Asadollahi Parisa , Dranbandi Atieh , Navidifar Tahereh , Ghanavati Roya 
Published: February 2022

AbstractIntroductionCoronavirus disease 2019 (COVID‐19) and acquired immune deficiency syndrome (AIDS) are two viral diseases for which there are currently no definitive treatments. Nowadays, because of the health system's focus on the COVID‐19 epidemic, the control of human immunodeficiency virus (HIV) has received less attention. In this review, we will discuss the characteristics of COVID‐19 in HIV‐positive patients.Material and MethodsUsing the PRISMA guideline, the databases of Scopus, PubMed, and Web of Science were searched systematically from January 1, 2019 to February 24, 2021. The following keywords were used: “Human Immunodeficiency Virus,” “acquired immune deficiency syndrome,” “HIV,” “AIDS,” “COVID‐19,” “severe acute respiratory syndrome coronavirus 2,” “novel coronavirus,” “SARS‐CoV‐2,” “nCoV disease,” “SARS2,” and “2019‐nCoV disease.”ResultsTwenty‐one percent of studies were conducted in the USA (n = 13), 16% in China (n = 10), and 13% in Italy (n = 8), respectively. The majority of the patients were men (74.3%). Tenofovir disoproxil fumarate was used in 47.4% of patients, emtricitabine in 58.4%, and lamivudine in 34.8% to treat HIV. Symptoms of HIV patients with COVID‐19 included coughing (81.3%), fever (62.8%), and dyspnea (60%). Hydroxychloroquine (39.34%) and azithromycin (36.58%) were the common treatment options for COVID‐19. The total death rate in HIV‐positive patients with COVID‐19 was about 9%.ConclusionIn the current systematic review, we demonstrated that HIV‐positive patients co‐infected with COVID‐19 have high comorbidity of hypertension and diabetes mellitus. HIV/COVID‐19 co‐infection might have negatively influenced the HIV treatment and diagnosis, which indicates the need to regularly screen HIV patients in the COVID‐19 pandemic.
Systematic review and meta‐analysis of protein intake to support muscle mass and function in healthy adults
Authors: Nunes Everson A. , Colenso‐Semple Lauren , McKellar Sean R. , Yau Thomas , Ali Muhammad Usman , Fitzpatrick‐Lewis Donna , Sherifali Diana , Gaudichon Claire , Tomé Daniel , Atherton Philip J. , Robles Maria Camprubi , Naranjo‐Modad Sandra , Braun Michelle , Landi Francesco , Phillips Stuart M. 
Published: February 2022

AbstractWe performed a systematic review, meta‐analysis, and meta‐regression to determine if increasing daily protein ingestion contributes to gaining lean body mass (LBM), muscle strength, and physical/functional test performance in healthy subjects. A protocol for the present study was registered (PROSPERO, CRD42020159001), and a systematic search of Medline, Embase, CINAHL, and Web of Sciences databases was undertaken. Only randomized controlled trials (RCT) where participants increased their daily protein intake and were healthy and non‐obese adults were included. Research questions focused on the main effects on the outcomes of interest and subgroup analysis, splitting the studies by participation in a resistance exercise (RE), age (<65 or ≥65 years old), and levels of daily protein ingestion. Three‐level random‐effects meta‐analyses and meta‐regressions were conducted on data from 74 RCT. Most of the selected studies tested the effects of additional protein ingestion during RE training. The evidence suggests that increasing daily protein ingestion may enhance gains in LBM in studies enrolling subjects in RE (SMD [standardized mean difference] = 0.22, 95% CI [95% confidence interval] 0.14:0.30, P < 0.01, 62 studies, moderate level of evidence). The effect on LBM was significant in subjects ≥65 years old ingesting 1.2–1.59 g of protein/kg/day and for younger subjects (<65 years old) ingesting ≥1.6 g of protein/kg/day submitted to RE. Lower‐body strength gain was slightly higher by additional protein ingestion at ≥1.6 g of protein/kg/day during RE training (SMD = 0.40, 95% CI 0.09:0.35, P < 0.01, 19 studies, low level of evidence). Bench press strength is slightly increased by ingesting more protein in <65 years old subjects during RE training (SMD = 0.18, 95% CI 0.03:0.33, P = 0.01, 32 studies, low level of evidence). The effects of ingesting more protein are unclear when assessing handgrip strength and only marginal for performance in physical function tests. In conclusion, increasing daily protein ingestion results in small additional gains in LBM and lower body muscle strength gains in healthy adults enrolled in resistance exercise training. There is a slight effect on bench press strength and minimal effect performance in physical function tests. The effect on handgrip strength is unclear.